IPI-145: Clinical Trials

6 trials of IPI-145, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed. 6 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 6
Phase 1	1	Completed 1

Follow IPI-145: new trials by email Literature Review of IPI-145 trials Research Report on IPI-145

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma	Phase 2	Completed	SecuraBio	103	2019-09-24	2024-09-19
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Duvelisib, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome	Phase 1 / Phase 2	Completed	Dana-Farber Cancer Institute	55	2018-07-12	2026-10-28
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib - Peripheral T-cell Lymphoma	Phase 2	Completed	SecuraBio	156	2018-02-22	2025-03-07
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) Duvelisib - Hematologic Malignancy	Phase 2	Completed	SecuraBio	19	2016-04-01	2023-09-11
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma	Phase 2	Completed	SecuraBio	129	2013-06-17	2023-09-07
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone IPI-145, Placebo - Rheumatoid Arthritis	Phase 2	Completed	SecuraBio	322	2013-04-01	2021-03-17

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding